This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
1 Apr 2011

Invida & Roche Ink Pact for Portfolio in Korea

Roche Korea has restructured for 2011 as part of its recently announced Operational Excellence Program.

Invida Group Pte Ltd. has reached a partnership agreement with Roche for the commercialization and marketing of Roche’s primary care portfolio throughout Korea. Invida will be responsible for the commercialization of these products and will allow Roche to focus on its specialty care portfolio in Korea.

Invida will manage all marketing and sales activities for Roche’s primary care products, including Xenical and Roaccutane, as well as products from Roche’s CNS portfolio, including Madopar for the treatment of Parkinson’s disease and Rivotril for epilepsy and Valium. Roche Korea has restructured for 2011 as part of its recently announced Operational Excellence Program.

Mark Brown, general manager, Invida Korea, commented, “We are excited to partner with Roche and provide them with the vital infrastructure to promote these products in

Related News